Caroline Kovac

Views:
 
     
 

Presentation Description

No description available.

Comments

Presentation Transcript

Healthcare and Lifesciences –Changing the World …Everyday: 

Healthcare and Lifesciences – Changing the World …Everyday China Lifesciences Partnering Forum January, 2006 Dr. Caroline A. Kovac General Manager IBM Healthcare and Life Sciences

The Next 10 Years: 

The Next 10 Years We are at the beginning of a period of transformational change in human healthcare The ‘tipping point’ will be accelerated by: Changing demographics New economic models Technological innovation Globalization The transformation of healthcare in the next ten years will threaten some existing business models, but offer extraordinary opportunities as well.

The Human Genome – A Starting Point Not an Endpoint: 

The Human Genome – A Starting Point Not an Endpoint But now the real challenge – translating this base of knowledge into meaningful diagnostics and innovative new therapies and treatments. The life sciences, pharmaceutical and healthcare systems must undergo fundamental, structural change to achieve the promise of personalized medicine….Information technology will play a decisive, transformative role.

New Drivers of R&D: 

New Drivers of Randamp;D Manufacturing Biologics Technology Change Systems Biology Regulatory Change Drug/indicationandgt;Mutation Therapeuticsandgt;Theranostics (Rx/Dx) Market Place Change Generics New Markets (obesity/memory/aging)andgt;Old Markets (cancer/CV) Personalizedandgt;Predictiveandgt;Preventative medicine Source: Burrill and Company, 2005

Slide5: 

Safety-Based Drug Withdrawals Combined peak sales was in excess of $11 Billion Sources: Goldman Sachs, Med Ad News Neurontin® Increasingly Rapid Generic Erosion Pipeline Failures and Delays Blockbuster US Patent Expiries, 2002-2007 VIOXX 2004 Challenges in the Life Sciences Industry

Cost of Development has more than doubled between 1980 and 1990: 

Cost of Development has more than doubled between 1980 and 1990 Cost per Patient in Phases I-III* Clinical Trials, 1989-1997 *Out-of-pocket investigator and central laboratory cost per patient. Source: Tufts, CSDD 'Outlook2001'; Parexel Pharma Randamp;D Sourcebook 2001, p. 113 Average Cost to Develop a New Drug, from Discovery to Approval ($millions) CAGR 5.4%

Market Cap Comparison: Biotech vs Big Pharma: 

Market Cap Comparison: Biotech vs Big Pharma Source: Burrill and Company, 2005

Slide8: 

True North, Advisory Board Council, Advancing the Patient Safety Agenda, 2004 www.healthalliant.com : Bureau of Economic Analysis 202-606-9900 CMS 877-267-2323 Cms.gov/statistics/nhe Challenges in the Healthcare Industry Patient Safety Cost Compliance Productivity

Aging Population in the US will increase the number of patients in Heart Disease: 

Aging Population in the US will increase the number of patients in Heart Disease BB BB AGE WHEN INCIDENCE OF CHD INCREASES AMERICAN HEART ASSOCIATION 2002

Many New Players in an Emerging Market: 

Many New Players in an Emerging Market Health and Wellness Market Diagnostics Consumer Products Companies Pharmaceutical Companies Biotechs Genomics Agriculture and Food Companies Employers and Government

This transformation is being accelerated by a combination of revolutionary technologies and evolutionary practices: 

This transformation is being accelerated by a combination of revolutionary technologies and evolutionary practices Personalized Health Care Translational Medicine Health Care Today BioMedical Imaging Episodic Treatment Electronic Health Records Artificial Expert Systems Clinical Genomics Genetic Predisposition Testing Molecular Medicine CA Diagnosis Pre-symptomatic Treatment Lifetime Treatment

Slide12: 

Healthcare and Life Sciences are part of the same ecosystem Basic Research and Discovery Pharmaceutical and Biotech Diagnostics and Medical Devices Academic Medical Research Centers Integrated Care Delivery Networks Community Hospitals and Practices Payors Private, Government, Employers Life Sciences Healthcare Providers

Information Based Medicine: 

Information Based Medicine A system of medical care which supplements traditional opinion-based diagnoses with new insights gleaned through computerized data acquisition, management and analysis. The goal of Information-Based Medicine (IBM) is to improve treatment outcomes by improving the accuracy of diagnostic decisions.

Slide14: 

Information Based Medicine will require unprecedented access to diverse, integrated information Challenges Volume and complexity of data Integrating massive volumes of disparate data Need for sophisticated analytics Growing collaboration across ecosystem

Slide15: 


Slide16: 


Slide17: 

TPMT Genotype Test for Leukemia Patients CYP Test to determine drug metabolism HER2 Test + Rise of Dx/Rx Bundles 'Theranostics' Targeted Treatments

Slide18: 


Medical Imaging is a Growing Market: 

Medical Imaging is a Growing Market US imaging market growing 10-12% China imaging market growing 25%+

Mobile Health Monitoring: Solutions for Chronic Disease Management?: 

Mobile Health Monitoring: Solutions for Chronic Disease Management? Chronic disease – diabetes, congestive heart failure, etc. – accounts for 75% of medical costs in the US Disease management can substantially improve patient outcomes and lower cost Medical devices and telecommunications technologies are converging to develop monitoring and control systems for patients with chronic disease

The “global-ness” of Biotech: 

The 'global-ness' of Biotech Science/technology Intellectual property/patents/FTO People Communications Competition Capital Markets—diseases know no borders Even the smallest biotech is a global player

Convergence of IT and Biology : 

Convergence of IT and Biology Life Sciences Information Technology

Slide23: 


authorStream Live Help